NYSE$OKLO
Oklo Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Oklo reported Q2 2025, net loss of $24.7M, diluted EPS of $-0.18.
For Q2 2025, Oklo reported a net loss of $24.7M, diluted EPS was $-0.18. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $24.7M.
- Diluted EPS $-0.18.
- Oklo MD&A highlights liquidity, capital, and core trends.
- Segment and macro factors shape year-over-year comparisons.
Headline financials
Revenue & EPS history
Oklo · Revenue · Quarterly
$0
Forward guidance
Clinical-stage and growth biotech discuss trial milestones, cash runway, and partnership optionality.
Tailwinds
- Pipeline progress and data readouts.
- Cash runway from recent financings.
- Licensing or collaboration potential.
Headwinds
- Trial failure or regulatory delays.
- Dilution from equity raises.
- Commercialization timing uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q2 2025
+1.9%
Avg return
Earnings day
-5.1%
Avg return
5 days after
+3.4%
Avg return
30 days after
55%
6 / 11 earnings
Positive
+15.6%
Q1 2024
Best reaction
-6.9%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.5% | -20.3% | -21.3% | |
| Q3 2025 | +7.9% | -8.5% | -16.1% | |
| Q2 2025 | +9.2% | -1.1% | +11.3% | |
| Q1 2024 | +15.6% | +24.0% | +98.8% | |
| Q4 2024 | -6.9% | -27.6% | -21.3% | |
| Q3 2024 | -3.9% | -25.2% | -23.6% | |
| Q4 2023 | +0.4% | +0.9% | +6.2% | |
| Q3 2023 | -0.2% | +0.0% | +0.5% | |
| Q2 2023 | -0.1% | -0.1% | +0.2% | |
| Q1 2023 | +0.4% | +1.3% | +2.0% | |
| Q4 2022 | +0.2% | +0.0% | +1.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro